Stem cell science in India: emerging economies and the politics of globalization

Bibliography

• 1  UK Stem Cell Initiative: Report and Recommendations. Department of Health, London, UK (2005).
  Google Scholar
• 2  Archibugi D, Michie J: Technology, Globalisation and Economic Performance. Cambridge University Press, Cambridge, UK (1997).
  Google Scholar
• 3  Levine AD: Research policy and the mobility of US stem cell scientists. Nat. Biotechnol.24(7),865–866 (2006).
  Medline CASGoogle Scholar
• 4  Ross A: Fast Boat to China: Corporate Flight and the Consequences of Free Trade; Lessons from Shanghai. Pantheon, NY, USA (2006).
  Google Scholar
• 5  Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA (2006).
  Google Scholar
• 6  Smith RD: Foreign direct investment and trade in health services: a review of the literature. Soc. Sci. Med.59,2313–2323 (2004).
  MedlineGoogle Scholar
• 7  Enriquez J: Might a Bell Toll for US Pharma? Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Center, NY, USA 65–66 (2006).
  Google Scholar
• 8  Subramanian S: Chasing China: can India bridge the gap? In: Asia’s Giants: Comparing China and India. Friedman E, Gilley B (Eds). Palgrave Macmillan, NY, USA 77–95 (2005).
  Google Scholar
• 9  Fitzgerald M: Where the money is. Nat. Biotechnol.24,240–242 (2006).
  Medline CASGoogle Scholar
• 10  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A5-141 (2006).
  Google Scholar
• 11  Sur M: Breathing life into biology. Nature outlook: India. Nature436,487 (2005).
  Medline CASGoogle Scholar
• 12  Jayaraman KS: Among the best. Nature outlook: India. Nature436,483 (2005).
  Google Scholar
• 13  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-122–A2-123 (2006).
  Google Scholar
• 14  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-32 (2006).
  Google Scholar
• 15  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A3-54–A3-55 (2006).
  Google Scholar
• 16  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-96 (2006).
  Google Scholar
• 17  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A5-97 (2006).
  Google Scholar
• 18  World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition.) WIPO, 7 (2006).
  Google Scholar
• 19  World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition.) WIPO, 10 (2006).
  Google Scholar
• 20  World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition.) WIPO, 16 (2006).
  Google Scholar
• 21  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A6-53 (2006).
  Google Scholar
• 22  Kumar K, Quach U, Thorsteindottir H, Somsekhar H, Daar A, Singer P: Indian biotechnology – rapidly evolving and industry led. Nat. Biotechnol.22(Suppl.),DC33 (2004).
  Google Scholar
• 23  National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A6-5–A6-9 (2006).
  Google Scholar
• 24  Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 55 (2006).
  Google Scholar
• 25  Padma TV: India’s drug tests. Nature436,485 (2005).
  Medline CASGoogle Scholar
• 26  Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA, 56 (2006).
  Google Scholar
• 27  National Science Board: Science and Engineering Indicators 2006. (Volume 2) National Science Foundation, Arlington, VA, USA A4-87 (2006).
  Google Scholar
• 28  Jayaraman KS: Biotech boom. Nature436,481 (2005).
  CASGoogle Scholar
• 29  The scientific balance of power. Nature439(7077),646–647 (2006).
  MedlineGoogle Scholar
• 30  Verma I: Then and now. Nature436,479 (2005).
  Google Scholar
• 31  Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 16–17 (2006).
  Google Scholar
• 32  Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 54 (2006).
  Google Scholar
• 33  Sethi S: Venture capital reforms: give me more on the platter. The Economic Times, 31 January (2001).
  Google Scholar
• 34  Bharadwaj A: Cultures of embryonic stem cell research in India. In: Crossing Borders. Cultural, Religious and Political Differences Concerning Stem Cell Research, a Global Approach. Bender W, Hauskeller, C, Manzei A (Eds). Agenda Verlag, Munster, Germany 331–333 (2005).
  Google Scholar
• 35  Bharadwaj A: Why adoption is not an option in India: the visibility of infertility, the secrecy of donor insemination, and other cultural complexities. Soc. Sci. Med.56,1867–1880 (2003).
  MedlineGoogle Scholar
• 36  Padma TV: India’s drug tests. Nature436,485 (2005).
  Medline CASGoogle Scholar
• 37  Padma TV: Rivalry and red tape. Nature436,490–491 (2005).
  MedlineGoogle Scholar
• 38  Mudur M: India plans to audit clinical trials. BMJ331,1044 (2005).
  MedlineGoogle Scholar
• 39  Padma TV. Unchecked by guidelines, Indian stem cell scientist rush ahead. Nat. Med.12(1),4 (2006).
  Medline CASGoogle Scholar
• 40  Ramesh R: Row over doctor’s ‘miracle cures’. Guardian 18 November (2005).
  Google Scholar
• 41  Godall S, Janssens B, Wagner K, Wong J, Woods W, Yeh M: The promise of the East: India and China as R & D options. Nat. Biotechnol.24(9),1061–1064 (2006).
  MedlineGoogle Scholar
• 42  Mudur F: India plans to audit clinical trials. BMJ331,1044–1045 (2006).
  Google Scholar
• 43  Perrin N: The Global Commercialisation of UK Stem Cell Research. UKTI (2005).
  Google Scholar
• 101  Stem Cell Research Forum of India www.scrfi.org
  Google Scholar
• 102  SciDevNet www.scidev.net/News/index.cfm?fuseaction=readnews&itemid=1849&language=1
  Google Scholar
• 103  Task force to seek funds for stem cell research. The Hindu Business Line www.thehindubusinessline.com/2005/04/06/stories/2005040601270900.htm
  Google Scholar
• 104  Perrin N: The Global Commercialisation of Stem Cell Research. London, UK Trade and Investment www.chrismason.com/industry_library/assets/UKTI%20Stem%20Cell%20Res.pdf
  Google Scholar
• 105  BBC News: Centre to sell human stem cells http://news.bbc.co.uk/1/hi/scotland/5383464.stm
  Google Scholar
• 106  Arnold W: Singapore fills stem-cell void created by a US ban. International Herald Tribune. Business www.iht.com/articles/2006/08/17/business/stem.php
  Google Scholar
• 107  Kenney M: India, China and offshoring. http://hcd.ucdavis.edu/faculty/kenney/articles/indiachinaoffshoring.htm
  Google Scholar
• 108  Kearney AT: Fishing for opportunities: successful clinical trials management. Pharmaceutical Executive. www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=333301
  Google Scholar
• 109  Presentation by Professor Brian Clark, Life Sciences Partnering China and Europe. www.e?unlimited.com/LSPCE/Event/London2006/default.asp?mp=presentations.asp
  Google Scholar
• 110  BuyUSAinfo. http://buyusainfo.net/docs/x_4140345.pdf
  Google Scholar
• 111  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 20 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 112  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 21 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 113  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 19 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 114  Kearney AT: Fishing for opportunities: successful clinical trials management. Pharmaceutical Executive. www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=333301
  Google Scholar
• 115  Ramani SV: Creating incentives: a comparison of government strategies in India and France, Biotechnology and Development Monitor, 26, 2 (1996). www.biotech-monitor.nl/2605.html
  Google Scholar
• 116  Department of Biotechnology, India http://dbtindia.nic.in/programmes/progmain.html
  Google Scholar
• 117  UK Stem Cell Initiative. Global Positions in Stem Cell Research. www.advisorybodies.doh.gov.uk/uksci/global/index.htm
  Google Scholar
• 118  UK Stem Cell Initiative. Global positions in stem cell research. www.advisorybodies.doh.gov.uk/uksci/global/index.htm
  Google Scholar
• 119  Nair MD: Stem cells research – promises and problems. Pharmabiz.com. www.pharmabiz.com/article/detnews.asp?articleid=11367&sectionid=46
  Google Scholar
• 120  Chaturvedi S: Dynamics of biotechnology research and industry in India: Statistics, perspectives and key policy issues. Statistical Analysis of Science, Technology and Industry Working Paper 2005/6. Directorate for Science, Technology and Industry, OECD, 27, 36 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 121  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical Analysis of Science, Technology and Industry Working Paper 2005/6. Directorate for Science, Technology and Industry, OECD, 16 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 122  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 37 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 123  Kumar S, Wilson N: Biotechnology in the limelight. Managing Intellectual Property. Supplement. Life Sciences 2006. www.managingip.com/?Page=17&ISS=21668&SID=623649
  Google Scholar
• 124  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 41 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 125  www.biotech.co.in/index.asp
  Google Scholar
• 126  Ramani SV: Creating incentives: a comparison of government strategies in India and France’, Biotechnology and Development Monitor www.biotech-monitor.nl/2605.htm,
  Google Scholar
• 127  Chaturvedi S: Dynamics of biotechnology research and industry in India: statistics, perspectives and key policy issues. Statistical analysis of science, technology and industry working paper 2005/6. Directorate for Science, Technology and Industry, OECD, 44–47 (2005). www.oecd.org/dataoecd/43/35/34947073.pdf
  Google Scholar
• 128  ICICI Venture www.iciciventure.com
  Google Scholar
• 129  Jayaraman KS: India seeks to block trade in human embryos. Science and Development Network. www.scidev.net
  Google Scholar
• 130  Express Healthcare Management. India cracks down to prevent embryo trade. Express Healthcare Management. www.expresshealthcaremgmt.com/20011015/editorial3.htm
  Google Scholar
• 131  Kahn J: A nation of guinea pigs: how India became the global hot spot for clinical trials.Wired Magazine 14(3) (2006). www.wired.com/wird/archive/14.03/indiadrug.html
  Google Scholar
• 132  Indian Council of Medical Research Department of Biotechnology: guidelines for stem cell research and therapy www.icmr.nic.in/stem_cell/Stem_cell_guidelines.pdf
  Google Scholar
• 133  Indian Council of Medical Research, New Delhi: ethical guidelines for biomedical research on human subjects www.icmr.nic.in/ethical.pdf
  Google Scholar
• 134  Hypeandhope.com. Government to formulate operational guidelines for stem cell research. www.hypeandhope.com/wt/page/index/it_1132175492
  Google Scholar
• 135  Basu I: India’s clinical trials and tribulations. Asia Times, 23 July (2005). www.atimes.com/atimes/South_Asia/FG23Df03.html
  Google Scholar